IMMUNOGEN INC

Immunogen Inc. specializes in the manufacturing of pharmaceutical preparations, with a focused expertise in the development and production of specialized drugs, including hematology-related therapeutics. The company’s technical capabilities center on GMP-compliant pharmaceutical manufacturing processes, formulation science, and quality assurance systems essential for delivering sterile and biologically active drug products to regulated healthcare environments. Their work supports the production of complex drug substances requiring precise control over purity, stability, and dosing—critical for clinical and veteran healthcare applications. While specific therapeutic modalities are not detailed in available records, their focus on pharmaceutical preparation suggests deep proficiency in aseptic processing, lyophilization, and drug product finalization under FDA and VA compliance frameworks. The company has demonstrated direct engagement with the Department of Veterans Affairs, supplying pharmaceutical products under the Federal Supply Schedule for drugs, hematology agents, and related therapeutics. This relationship indicates alignment with VA’s mission to provide high-quality, reliable medications to veteran populations, likely supporting specialty pharmacy programs, oncology care, and blood disorder treatments. Immunogen Inc. operates primarily within NAICS 325412, which encompasses the manufacturing of finished pharmaceutical products from active ingredients. Their market positioning is narrow but critical—focused on the production of clinically essential drug formulations rather than broad-spectrum generics or over-the-counter products. This specialization positions them as a niche supplier within the federal pharmaceutical supply chain, serving high-acuity medical needs. As a 2L entity headquartered in Waltham, Massachusetts, Immunogen Inc. is structured as a small business with no federal certifications disclosed. Their geographic presence is centered in the biopharmaceutical corridor of eastern Massachusetts, leveraging regional expertise in life sciences manufacturing. The company’s government market footprint is defined by precision pharmaceutical delivery to federal healthcare systems, particularly those serving specialized patient populations.